Discuss the relationship between the liver and haemostasis

Alexandra hopkins 21305919

Haemostasis is a vital physiological process that helps stop bleeding after damage to blood vessels. The liver plays an essential role in maintaining a healthy haemostasis, as it is a multifunctional organ. It contributes to haemostasis by synthesizing clotting factors, regulating platelet activity, and removing activated clotting factors. However, if the liver is not functioning properly, it can cause substantial changes to haemostasis, leading to either bleeding problems or thrombotic complications. This essay will explore the relationship between liver cirrhosis and haemostasis, covering the liver's role in haemostasis, the causes and cellular changes in liver cirrhosis, its impact on haemostasis, and the effectiveness of current and new treatment approaches.

In regard to haemostasis liver function is vital as it is involved in several aspects. For example, the liver synthesizes coagulation factors which are proteins in the blood that assist in clotting, such as prothrombin, fibrinogen as well as factor V, VII, IX, X, XI, XII. The liver also ensures that these clotting factors are cleared from the blood circulation ensuring a balanced coagulation process. To further ensure a balanced coagulation process the liver synthesizes anti-coagulation proteins such as antithrombin, protein S and C, these anticoagulants prevent excess clotting.

Liver cirrhosis is a chronic, progressive condition characterized by the irreversible scarring of the liver tissue. Various factors can cause cirrhosis of the liver however it is most commonly due to alcohol abuse, hepatitis, autoimmune diseases and non-alcoholic fatty liver disease. Liver cirrhosis can disrupt this delicate balance, leading to various haemostatic abnormalities.

In cirrhosis the liver experiences changes on a cellular level, the hepatocytes become damaged resulting in apoptosis, in an attempt to repair itself a buildup of fibrotic scar tissue occurs. Injury to the liver also stimulates hepatic stellate cells, as shown in *figure* 1, to transform into activated myofibroblasts further resulting in deposition of collagen-rich scar tissue. These cellular changes occurring as a result of cirrhosis distort the architecture of the liver commonly resulting in hepatocellular nodules, in the case of cirrhosis regenerative nodules are commonly found causing further disruption to liver function. The combined cellular change and architectural damage to the liver eventually results in fibrosis.

The impact liver cirrhosis has on haemostasis is calamitous and affects major mechanisms such as; a decrease in synthesizing factors, this leads to reduced levels of pro-coagulating factors resulting in a tendency to bleed more due to lack of the vital clotting factor; as mentioned above a vital role of the liver is to ensure a healthy balance of coagulating factors by clearing the bloodstream of anti-coagulating factors, a damaged liver is unable to maintain this balance leaving it in a hypercoagulable state putting patients at an increased risk of blood clots and possible thrombosis; cirrhosis can also lead to increased pressure in the portal vein as shown in *figure 1,* this is due to increased intraheptic vascular pressure caused by a change in liver structure as mentioned above, this pressure increase leads to varices in the gastrointestinal tract which can burst and bleed; patients with cirrhosis may also experience Thrombocytopenia a condition in which the body does not produce a sufficient amount of platelets, this can occur as a result of cirrhosis due to platelet sequestration in the spleen and decreased thrombopoietin (physiological regulator of platelet production) production in the liver.



Figure 1. changes to liver on cellular level in fibrosis compared to that of a healthy liver

The current approach to treating liver cirrhosis aims to manage underlying causes as well as alleviate symptoms and prevent complications. In the early stages of liver cirrhosis, lifestyle changes are essential for halting disease progression and maintaining general health. Chronic alcohol use causes inflammation and liver damage that can be reversed by quitting alcohol. Therefore, alcohol cessation is vital for people with liver cirrhosis brought on by alcohol, immediate and total abstinence from alcohol is necessary to halt the disease's progression. A well-balanced diet rich in fruits, vegetables, and whole grains, low in sodium and fats, can help ease symptoms and lessen complications like ascites (collection of fluid in the abdomen) and hepatic encephalopathy (neurological disorder). Maintaining a healthy weight and taking care of illnesses like diabetes and obesity can help improve liver function and slow the development of cirrhosis caused by NAFLD. Eating a diet high in antioxidants and anti-inflammatory nutrients may support liver health. Obese people who lose weight have a lower risk of developing cirrhosis and less fat buildup in their livers, obese patients would be encouraged to lower body fat in order to slow down progression of the disease. Obesity is the main cause of high blood pressure, this combined with increased portal vein pressure due to haemostatic change in the liver is a deadly combination and often results in rupture and internal bleeding in overweight cirrhosis patients. Liver cirrhotic people who regularly exercise can also benefit from this. Exercise can help manage obesity, increase cardiovascular health generally, and improve insulin sensitivity.

Medications may also be used to treat symptoms, reverse effects and slow the progression of cirrhosis these medications include; Diuretics, which are frequently prescribed to manage fluid retention and ascites, are among the medications that may be prescribed to help manage symptoms and stop further liver damage. By raising urine output, they aid in edema (limb swelling due to fluid retention) reduction. Spironolactone and furosemide are frequently used diuretics for this purpose. Lactulose and Rifaximin: These drugs are used to treat hepatic encephalopathy, a severe liver cirrhosis complication that impairs brain function. Ursodeoxycholic Acid (UDCA): UDCA is a naturally occurring bile acid and is occasionally prescribed for specific liver diseases like primary biliary cirrhosis. Lactulose aids may also be used to reduce the production of toxic substances in the gut, while rifaximin works as an antibiotic to target harmful gut bacteria and lower ammonia levels in the blood as they are found to be elevated in patients with cirrhosis due to decreased conversion of ammonia to urea by the liver. By reducing liver inflammation and bile duct damage, it has a hepatoprotective effect and may slow the progression of the disease; antiviral medications For people with viral hepatitis-related cirrhosis (e.g., hepatitis B or C),

antiviral medications can prevent viral replication and liver inflammation, potentially preventing further liver damage; Immunosuppressants: In cases of autoimmune liver diseases like autoimmune hepatitis or primary sclerosing cholangitis, immunosuppressant medications may be prescribed to lessen the immune system's attack on the liver.

Interventional Procedures are used in more severe cases of liver cirrhosis where medications and lifestyle changes are not effective enough to prevent further damage to the liver, these interventions include; Transjugular Intrahepatic Portosystemic Shunt (TIPS): TIPS is a procedure in which a shunt is placed to connect the portal vein with the hepatic vein, redirecting blood flow and reducing portal hypertension. It can be effective in managing refractory ascites and variceal bleeding; Paracentesis and Ascitic Drainage: These procedures involve removing excess fluid from the abdominal cavity (ascites) to relieve discomfort and prevent complications like spontaneous bacterial peritonitis; Variceal Banding or Sclerotherapy: These procedures are used to treat esophageal varices by either banding them to stop bleeding or injecting a sclerosing agent to close them off, reducing the risk of life-threatening bleeding; Liver transplantation remains the definitive treatment for end-stage liver cirrhosis when other therapies have failed or disease complications become life-threatening. However, the availability of donor organs limits the widespread application of this treatment option. To address this, living-donor liver transplantation (LDLT) has emerged as an alternative, where a portion of a healthy living donor's liver is transplanted into the recipient; Targeted Therapies: Research is ongoing to develop targeted therapies that can inhibit specific molecular pathways involved in liver fibrosis and cirrhosis progression. These therapies aim to slow or even reverse fibrosis, potentially reducing the need for liver transplantation and improving long-term outcomes; Cell-Based Therapies: Stem cell and regenerative medicine approaches are being explored as potential treatments for liver cirrhosis. Transplantation of hepatocytes or stem cells may help promote liver regeneration and restore function, offering a promising avenue for future treatments.

In conclusion, when it comes to maintaining vascular integrity and preventing excessive bleeding, the liver's relationship with haemostasis is crucial. Its multifaceted role includes the synthesis, elimination, and regulation of various coagulation factors, anticoagulants, and cellular components. However, liver dysfunction, which is frequently present in diseases like cirrhosis, distorts these complex processes and causes a variety of hemostatic abnormalities. A higher risk of bleeding or thrombosis is associated with liver-related hemoemostatic disorders, which have been shown in numerous studies to involve unbalanced coagulation factors, impaired cellular behavior and platelet dysfunction. Understanding the specifics of liver-mediated haemostasis' mechanistic underpinnings is essential for accurate diagnosis and treatment of such disorders and is a fundamental component of blood science. The current methods of treatment concentrate on treating the underlying liver disease and removing abnormalities. These treatments, however, may not effectively address the underlying cause because they focus more on managing symptoms. Fortunately, advances in medical research have resulted in the creation of specialized treatments for haemostatic disorders connected to the liver. The potential for more precise and efficient interventions to restore haemostatic balance in patients with liver cirrhosis is greatly increased by newer methodologies. Understanding the function of the liver in haemostasis and how it affects patient care is becoming more and more important as blood science develops. Finally, the intricate connection between the liver and haemostasis emphasizes the importance of the liver in preserving a delicate equilibrium between clotting and anticoagulation. Haemostasis changes brought on by cirrhosis need to be carefully considered because they can have a big effect on patient outcomes. We can continue to manage liver-related hemostasis disorders better by embracing novel research and therapeutic approaches, ultimately improving the quality of life for afflicted people and expanding the field of blood science as a whole.

References:

1. Flores, B., Trivedi, H.D., Robson, S.C. and Bonder, A. (2017). Hemostasis, bleeding and thrombosis in liver disease. *Journal of translational science*, [online] 3(3). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136435/.

2. Heinz, S. and Braspenning, J. (2015). Measurement of Blood Coagulation Factor Synthesis in Cultures of Human Hepatocytes. *Methods in molecular biology (Clifton, N.J.)*, [online] 1250, pp.309–16. doi:https://doi.org/10.1007/978-1-4939-2074-7_23.

3. Tripodi, A. (2015). Hemostasis abnormalities in cirrhosis. *Current Opinion in Hematology*, 22(5), pp.406–412. doi:https://doi.org/10.1097/moh.0000000000000164.

4. Palta, S., Saroa, R. and Palta, A. (2014). Overview of the coagulation system. *Indian Journal of Anaesthesia*, [online] 58(5), p.515. doi:https://doi.org/10.4103/0019-5049.144643.

5. Acharya, P., Chouhan, K., Weiskirchen, S. and Weiskirchen, R. (2021). Cellular Mechanisms of Liver Fibrosis. *Frontiers in Pharmacology*, 12. doi:https://doi.org/10.3389/fphar.2021.671640.

6. Hanna, R.F., Aguirre, D.A., Kased, N., Emery, S.C., Peterson, M.R. and Sirlin, C.B. (2008). Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features. *RadioGraphics*, 28(3), pp.747–769. doi:https://doi.org/10.1148/rg.283055108.

7. Healthline. (2023). *Cirrhosis and GI Bleeding: How Are They Linked?* [online] Available at: https://www.healthline.com/health/cirrhosis-and-gi-bleed#:~:text=Gastrointestinal%20bleeding%20is%20a%20common

8. Miyazaki, H. and Kato, T. (1999). Thrombopoietin: biology and clinical potentials. *International Journal of Hematology*, [online] 70(4), pp.216–225. Available at: https://pubmed.ncbi.nlm.nih.gov/10643146/#:~:text=Thrombopoietin%20(TPO)%20is%20the%20principal.

9. Cleveland Clinic. (n.d.). *Hepatic Encephalopathy: Types, Causes, Symptoms, Treatment*. [online] Available at: https://my.clevelandclinic.org/health/diseases/21220-hepatic-encephalopathy#:~:text=What%20is%20hepatic%20encephalopathy%3F.

10. www.hopkinsmedicine.org. (n.d.). *Ascites*. [online] Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/ascites#:~:text=Ascites%20is%20a%20condition%20in.

11. https://www.facebook.com/nhswebsite (2017). *Treatment for cirrhosis*. [online] nhs.uk. Available at: https://www.nhs.uk/conditions/cirrhosis/treatment/#:~:text=Dietary%20changes

12. British Liver Trust. (n.d.). *Diet and cirrhosis*. [online] Available at: https://britishlivertrust.org.uk/information-and-support/living-with-a-liver-condition/diet-and-liver-disease/cirrhosis-and-diet/.

13. Mayo Clinic (2023). *Edema - Symptoms and causes*. [online] Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/edema/symptoms-causes/syc-20366493#:~:text=Edema%20is%20swelling%20caused%20by.

14. www.apollopharmacy.in. (n.d.). *FUROSEMIDE+SPIRONOLACTONE: Uses, Side Effects and Medicines | Apollo Pharmacy*. [online] Available at: https://www.apollopharmacy.in/salt/FUROSEMIDE+SPIRONOLACTONE

15. www.aasld.org. (2021). *Why do we use Lactulose and Rifaximin for Hepatic Encephalopathy? | AASLD*. [online] Available at: https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-we-use-lactulose-and-rifaximin-hepatic#:~:text=Lactulose%20and%20Rifaximin%20(Xifaxan)%20are.

16. nhs.uk. (2017). *Primary biliary cholangitis (primary biliary cirrhosis) - Treatment*. [online] Available at: https://www.nhs.uk/conditions/primary-biliary-cholangitis-pbc/treatment/#:~:text=Ursodeoxycholic%20acid%20(UDCA)%20is%20the.

17. www.webmd.com. (n.d.). *Lactulose (For Encephalopathy) Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD*. [online] Available at: https://www.webmd.com/drugs/2/drug-12002-7202/lactulose-for-encephalopathy-oral/lactulose-liver-oral-rectal/details.

18. Caraceni, P., Vargas, V., Solà, E., Alessandria, C., Wit, K., Trebicka, J., Angeli, P., Mookerjee, R.P., Durand, F., Pose, E., Krag, A., Bajaj, J.S., Beuers, U., Ginès, P., Juanola, A., Napoleone, L.,

Carol, M., Avitabile, E., Thu, A.M. and Cervera, M. (2021). The Use of Rifaximin in Patients With Cirrhosis. *Hepatology*, 74(3), pp.1660–1673. doi:https://doi.org/10.1002/hep.31708.

19. Deutsch-Link, S., Moon, A.M., Jiang, Y., Barritt, A.S. and Tapper, E.B. (2022). Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends. *Clinical Therapeutics*, 44(3), pp.e45–e57. doi:https://doi.org/10.1016/j.clinthera.2022.01.008.

20. Cropley, A. and Weltman, M. (2017). The use of immunosuppression in autoimmune hepatitis: A current literature review. *Clinical and Molecular Hepatology*, 23(1), pp.22–26. doi:https://doi.org/10.3350/cmh.2016.0089.

21. Mount Sinai Health System. (n.d.). *Transjugular intrahepatic portosystemic shunt (TIPS) Information | Mount Sinai - New York*. [online] Available at: https://www.mountsinai.org/health-library/surgery/transjugular-intrahepatic-portosystemic-shunt-tips#:~:text=Transjugular%20intrahepatic%20portosystemic%20shunt%20(TIPS)%20is%20a%20procedure%20that%20involves.

22. Milton Keynes University Hospital. (n.d.). *Large Volume Paracentesis - Ascites Drainage*. [online] Available at: https://www.mkuh.nhs.uk/patient-information-leaflet/large-volume-paracentesis-ascites-drainage

23. Lo, G., Lai, K., Cheng, J., Lin, C., Huang, J., Hsu, P. and Chiang, H. (1997). Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. *Hepatology*, 25(5), pp.1101–1104. doi:https://doi.org/10.1002/hep.510250509.

24. www.mayoclinic.org. (n.d.). *Liver transplant - Mayo Clinic*. [online] Available at: https://www.mayoclinic.org/tests-procedures/liver-transplant/about/pac-20384842#:~:text=When%20cirrhosis%20occurs%2C%20scar%20tissue